home / stock / lgvn / lgvn articles

LGVN Articles, Longeveron Inc. - From 12/21/23

Stock Information
Company Name: Longeveron Inc.
Stock Symbol: LGVN
Market: NASDAQ
Website: longeveron.com
Menu
LGVN LGVN Quote LGVN Short LGVN News LGVN Articles LGVN Message Board
Get LGVN Alerts

News, Short Squeeze, Breakout and More Instantly...
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Benzinga

MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company devel...
Why Longeveron (LGVN) Shares Are Falling Sharply | Benzinga

Longeveron Inc (NASDAQ: LGVN) shares are trading lower by 22.8% to $1.25 Thursday morning after the company has finalized an agreement for a r...

Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Benzinga

MIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company devel...

Longeveron (NASDAQ: LGVN) Announces Positive Top-Line Results For Its Phase 2a Clinical Trial For The Treatment Of Mild Alzheimer's Disease with Lomecel-B™ | Benzinga

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions using cell...
Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association | Benzinga

Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct...

Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 | Benzinga

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnolo...

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer's | Benzinga

LOS ANGELES, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via IBN -- Longeveron Inc. (NASDAQ:LGVN), a clinical-stage biotechnology company developing regen...
Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Benzinga

MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company devel...

Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session | Benzinga

Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin...

Longeveron's Alzheimer's Candidate Meets Safety Goal In Mid-Stage Study | Benzinga

Longeveron Inc (NASDAQ: LGVN) announced topline results from the Phase 2a trial of its investigational product Lomecel-B for mild Alzheim...
Previous 10 Next 10